All You Need to Know About DuPont de Nemours (DD) Rating Upgrade to Buy

23.12.24 18:00 Uhr

Werte in diesem Artikel
Aktien

73,48 EUR -0,35 EUR -0,47%

Indizes

5.974,1 PKT 43,2 PKT 0,73%

DuPont de Nemours (DD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for DuPont de Nemours is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for DuPont de Nemours imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.Earnings Estimate Revisions for DuPont de NemoursFor the fiscal year ending December 2024, this specialty chemicals maker is expected to earn $3.91 per share, which is a change of 12.4% from the year-ago reported number.Analysts have been steadily raising their estimates for DuPont de Nemours. Over the past three months, the Zacks Consensus Estimate for the company has increased 4.6%.Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.You can learn more about the Zacks Rank here >>>The upgrade of DuPont de Nemours to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DuPont de Nemours, Inc. (DD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf DuPont de Nemours

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DuPont de Nemours

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu DuPont de Nemours

Analysen zu DuPont de Nemours

DatumRatingAnalyst
04.10.2021DuPont de Nemours OverweightJP Morgan Chase & Co.
20.08.2019DowDuPont OutperformCowen and Company, LLC
25.06.2019DowDuPont NeutralMonness, Crespi, Hardt & Co.
10.06.2019DowDuPont OutperformCowen and Company, LLC
06.02.2019DowDuPont Market PerformCowen and Company, LLC
DatumRatingAnalyst
04.10.2021DuPont de Nemours OverweightJP Morgan Chase & Co.
20.08.2019DowDuPont OutperformCowen and Company, LLC
10.06.2019DowDuPont OutperformCowen and Company, LLC
12.10.2018DowDuPont buyDeutsche Bank AG
29.03.2018DowDuPont OutperformBMO Capital Markets
DatumRatingAnalyst
25.06.2019DowDuPont NeutralMonness, Crespi, Hardt & Co.
06.02.2019DowDuPont Market PerformCowen and Company, LLC
12.09.2017DowDuPont NeutralMonness, Crespi, Hardt & Co.
31.05.2017Dow Chemical Market PerformCowen and Company, LLC
26.04.2017DuPont (E I DuPont de Nemours and Sector PerformRBC Capital Markets
DatumRatingAnalyst
05.01.2009Dow Chemical verkaufenEuro am Sonntag
11.04.2007Dow Chemical verkaufenHamburger Sparkasse
03.02.2006Update Rohm and Haas Co.: ReduceUBS
07.07.2005Update Rohm and Haas Co.: SellLongbow

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DuPont de Nemours nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"